Daily intake of Mucuna pruriens in advanced Parkinson's disease: A 16-week, noninferiority, randomized, crossover, pilot study

Cilia, Roberto; Laguna, Janeth; Cassani, E.; Cereda, Emanuele; Raspini, Benedetta; Barichella, Michela; Pezzoli, Gianni

doi:10.1016/j.parkreldis.2018.01.014

Cited by 45 publications

(21 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The gut microbiota provides an important role in the efficacy of bacopa through these mechanisms. While previous human studies in non-clinical populations have elucidated some of the beneficial effects of bacopa on memory and cognitive impairment, 129 , 130 , 153 human clinical trials using bacopa in neurodegenerative disease are lacking and warranted.…”

Section: Therapeutic Opportunities and The Gut Brain Axismentioning

confidence: 99%

Dysfunction of the Microbiota-Gut-Brain Axis in Neurodegenerative Disease: The Promise of Therapeutic Modulation With Prebiotics, Medicinal Herbs, Probiotics, and Synbiotics

Peterson

2020

J Evid Based Complementary Altern Med

View full text Add to dashboard Cite

Recent data suggest gut microbiota dysbiosis as a contributing factor in neurodegenerative diseases, such as Parkinson’s Disease (PD) and Alzheimer’s Disease (AD), and these pathologies may manifest via the microbiota-gut-brain-axis, which comprises bidirectional communication through neuroimmune, neuroendocrine, and direct neural pathways such as the vagus nerve. Preclinical and human clinical trial data reveal exciting potential for novel treatment targets and therapeutic modulation with prebiotics, medicinal herbs, probiotics, and synbiotics in health, aging, and neurodegeneration and are reviewed here. While greater insights and characterization of the microbiota-gut-brain axis have been revealed over the past decade, salient questions related to the pathology, pathogenesis and clinical treatment of the axis in the context of both health and neurodegenerative disease remain and are discussed in this review. Future directions such as additional well-controlled, large scale, longitudinal human clinical trials are urgently needed to further elucidate both mechanism and therapeutic opportunity in health, neurological disease, and disease subpopulations to ensure that the next decade ushers the dawn of targeted therapeutic modulation of the microbiota-gut-brain axis.

show abstract

Section: Therapeutic Opportunities and The Gut Brain Axismentioning

confidence: 99%

Dysfunction of the Microbiota-Gut-Brain Axis in Neurodegenerative Disease: The Promise of Therapeutic Modulation With Prebiotics, Medicinal Herbs, Probiotics, and Synbiotics

Peterson

2020

J Evid Based Complementary Altern Med

View full text Add to dashboard Cite

show abstract

“…Поскольку прием однократной дозы Mucuna pruriens оказался не уступающим поступающим в продажу препаратам леводопы, той же группой ученых было проведено 16-недельное рандомизированное исследование ежедневного потребления Mucuna pruriens при прогрессирующей болезни Паркинсона [39]. Четырнадцать пациентов с двигательными флуктуациями и дискинезиями получали порошок Mucuna pruriens (полученный из семян) и леводопу/карбидопу (LD/CD) в рандомизированном порядке и перекрестном дизайне в течение 16-недельного периода.…”

Section: результаты клинических исследованийunclassified

Review of Mucuna pruriens L. therapeutic potential for Parkinson’s disease

et al. 2020

View full text Add to dashboard Cite

Parkinson’s disease is a multifactorial disorder of the nervous system, the main features of which are progressive degeneration of dopaminergic neurons in the nigra pars compacta nigrostriatal tract and subsequent deficiency of the neurotransmitter dopamine in the areas of the brain, leading to the loss of motor function, the emergence of non-motor symptoms, rigidity, akinesia or bradykinesia, motor block, and decline in cognitive functions. Parkinson’s disease has high prevalence throughout the world, and has no curative treatment in modern medicine. The available drugs such as anticholinergics, levodopa and a DOPA-decarboxylase inhibitor provide symptomatic relief only. Although dopaminergic therapy is the standard treatment of motor disabilities associated with Parkinson’s disease, it does not managed all the aspects of the disease. For this reason, the increasing numbers of patients are looking for more holistic approach to the treatment of this disease. Mucuna pruriens L. – an annual self-pollinating legume plant, can be considered as a potential complementary therapy for patients with Parkinson’s disease, as it is an extremely rich source of levodopa. Numerous studies have shown that Mucuna pruriens extracts restore biochemical and behavioral abnormalities in animals with the experimental model of Parkinson’s disease. The plant also demonstrates some antioxidant activity. The clinical effects of high-dose Mucuna pruriens are similar to levodopa, but have a more favorable tolerance profile. If long-term use of Mucuna pruriens proves safe and effective in controlled clinical trials, it could become a sustainable complementary therapy for the treatment of Parkinson’s disease, especially in low-income countries.

show abstract

“…17,18 Table 1 showed the list of few phytopharmaceuticals and their therapeutic benefits. [19][20][21][22][23][24][25][26][27][28][29][30][31][32][33][34][35][36][37][38] India has a well-established long history of safe and continuous use of many herbal drugs and phytopharmaceuticals through officially recognized alternative systems of health viz. Ayurveda, Yoga, Unani, Siddha, Homeopathy and Naturopathy.…”

Section: Strengthmentioning

confidence: 99%

Opportunities and Challenges in Development of Phytopharmaceutical Drug in India- A SWOT Analysis

Singh¹,

Kalaivani²,

Srivastava³

et al. 2019

JYP

View full text Add to dashboard Cite

Background: India had issued a set of regulation for new class of plant based drug 'Phytopharmaceutical drug' as an amendment to the Drugs and Cosmetic Rules 1945. Age old traditional systems of medicine practiced in India 'Ayurveda', 'Siddha' and 'Unani' medicines. Ayurvedic, Siddha or Unani drugs include all medicines in accordance with the authoritative books of Ayurvedic, Siddha and Unani tibb. systems of medicine specified in the first Schedule of Drugs and Cosmetics Act 1940. Objective: The article aims to analyse opportunities and challenges in development of phytopharmaceutical drug in India through SWOT analysis. Methods: The Strength, Weakness, Opportunities and Threats (SWOT) in development of phytopharmaceutical drug in India was analysed through review of published literatures. Observation: The SWOT analysis showed that India being leader in the herbal industry has massive opportunity in national and international market for phytopharmaceutical drug. It was also observed that the phytopharmaceutical drug market has vital opportunity for expansion both in developed and developing countries. Conclusion: There is a need for investment and commitment in promoting research and development in the area of phytopharmaceutical drug.

show abstract

Daily intake of Mucuna pruriens in advanced Parkinson's disease: A 16-week, noninferiority, randomized, crossover, pilot study

Cited by 45 publications

References 19 publications

Dysfunction of the Microbiota-Gut-Brain Axis in Neurodegenerative Disease: The Promise of Therapeutic Modulation With Prebiotics, Medicinal Herbs, Probiotics, and Synbiotics

Dysfunction of the Microbiota-Gut-Brain Axis in Neurodegenerative Disease: The Promise of Therapeutic Modulation With Prebiotics, Medicinal Herbs, Probiotics, and Synbiotics

Review of Mucuna pruriens L. therapeutic potential for Parkinson’s disease

Opportunities and Challenges in Development of Phytopharmaceutical Drug in India- A SWOT Analysis

Contact Info

Product

Resources

About